Jerome A Yesavage1,2, J Kaci Fairchild1,2, Zhibao Mi3, Kousick Biswas3, Anne Davis-Karim4, Ciaran S Phibbs5,6, Steven D Forman7,8, Michael Thase9, Leanne M Williams1,2, Amit Etkin1,2,10, Ruth O'Hara1,2, Gerald Georgette1, Tamara Beale1, Grant D Huang11, Art Noda2, Mark S George12,13. 1. Department of Veterans Affairs, Sierra-Pacific Mental Illness Research Educational and Clinical Center, Palo Alto, California. 2. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. 3. Department of Veterans Affairs, Cooperative Studies Program Coordinating Center, Perry Point, Maryland. 4. Department of Veterans Affairs, Cooperative Studies Program Pharmacy Coordinating Center, Albuquerque, New Mexico. 5. Department of Veterans Affairs, Health Economics Resource Center and Center for Implementation to Innovation, Palo Alto, California. 6. Department of Pediatrics, Stanford University School of Medicine, Stanford, California. 7. Department of Veterans Affairs, Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. 8. Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 9. Department of Veterans Affairs, Veterans Affairs Medical Center, Philadelphia, Pennsylvania. 10. Stanford Neurosciences Institute, Stanford University, Stanford, California. 11. Department of Veterans Affairs, Cooperative Studies Program Central Office, Washington, DC. 12. Department of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina. 13. Brain Stimulation Laboratory, Psychiatry Department, Medical University of South Carolina, Charleston.
Abstract
Importance: Treatment-resistant major depression (TRMD) in veterans is a major clinical challenge given the high risk for suicidality in these patients. Repetitive transcranial magnetic stimulation (rTMS) offers the potential for a novel treatment modality for these veterans. Objective: To determine the efficacy of rTMS in the treatment of TRMD in veterans. Design, Setting, and Participants: A double-blind, sham-controlled randomized clinical trial was conducted from September 1, 2012, to December 31, 2016, in 9 Veterans Affairs medical centers. A total of 164 veterans with TRD participated. Interventions: Participants were randomized to either left prefrontal rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session) or to sham (control) rTMS treatment for up to 30 treatment sessions. Main Outcomes and Measures: The primary dependent measure of the intention-to-treat analysis was remission rate (Hamilton Rating Scale for Depression score ≤10, indicating that depression is in remission and not a clinically significant burden), and secondary analyses were conducted on other indices of posttraumatic stress disorder, depression, hopelessness, suicidality, and quality of life. Results: The 164 participants had a mean (SD) age of 55.2 (12.4) years, 132 (80.5%) were men, and 126 (76.8%) were of white race. Of these, 81 were randomized to receive active rTMS and 83 to receive sham. For the primary analysis of remission, there was no significant effect of treatment (odds ratio, 1.16; 95% CI, 0.59-2.26; P = .67). At the end of the acute treatment phase, 33 of 81 (40.7%) of those in the active treatment group achieved remission of depressive symptoms compared with 31 of 83 (37.4%) of those in the sham treatment group. Overall, 64 of 164 (39.0%) of the participants achieved remission. Conclusions and Relevance: A total of 39.0% of the veterans who participated in this trial experienced clinically significant improvement resulting in remission of depressive symptoms; however, there was no evidence of difference in remission rates between the active and sham treatments. These findings may reflect the importance of close clinical surveillance, rigorous monitoring of concomitant medication, and regular interaction with clinic staff in bringing about significant improvement in this treatment-resistant population. Trial Registration: ClinicalTrials.gov Identifier: NCT01191333.
RCT Entities:
Importance: Treatment-resistant major depression (TRMD) in veterans is a major clinical challenge given the high risk for suicidality in these patients. Repetitive transcranial magnetic stimulation (rTMS) offers the potential for a novel treatment modality for these veterans. Objective: To determine the efficacy of rTMS in the treatment of TRMD in veterans. Design, Setting, and Participants: A double-blind, sham-controlled randomized clinical trial was conducted from September 1, 2012, to December 31, 2016, in 9 Veterans Affairs medical centers. A total of 164 veterans with TRD participated. Interventions: Participants were randomized to either left prefrontal rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session) or to sham (control) rTMS treatment for up to 30 treatment sessions. Main Outcomes and Measures: The primary dependent measure of the intention-to-treat analysis was remission rate (Hamilton Rating Scale for Depression score ≤10, indicating that depression is in remission and not a clinically significant burden), and secondary analyses were conducted on other indices of posttraumatic stress disorder, depression, hopelessness, suicidality, and quality of life. Results: The 164 participants had a mean (SD) age of 55.2 (12.4) years, 132 (80.5%) were men, and 126 (76.8%) were of white race. Of these, 81 were randomized to receive active rTMS and 83 to receive sham. For the primary analysis of remission, there was no significant effect of treatment (odds ratio, 1.16; 95% CI, 0.59-2.26; P = .67). At the end of the acute treatment phase, 33 of 81 (40.7%) of those in the active treatment group achieved remission of depressive symptoms compared with 31 of 83 (37.4%) of those in the sham treatment group. Overall, 64 of 164 (39.0%) of the participants achieved remission. Conclusions and Relevance: A total of 39.0% of the veterans who participated in this trial experienced clinically significant improvement resulting in remission of depressive symptoms; however, there was no evidence of difference in remission rates between the active and sham treatments. These findings may reflect the importance of close clinical surveillance, rigorous monitoring of concomitant medication, and regular interaction with clinic staff in bringing about significant improvement in this treatment-resistant population. Trial Registration: ClinicalTrials.gov Identifier: NCT01191333.
Authors: Gregory A Fonzo; Madeleine S Goodkind; Desmond J Oathes; Yevgeniya V Zaiko; Meredith Harvey; Kathy K Peng; M Elizabeth Weiss; Allison L Thompson; Sanno E Zack; Steven E Lindley; Bruce A Arnow; Booil Jo; James J Gross; Barbara O Rothbaum; Amit Etkin Journal: Am J Psychiatry Date: 2017-07-18 Impact factor: 18.112
Authors: Keith S Dobson; Steven D Hollon; Sona Dimidjian; Karen B Schmaling; Robert J Kohlenberg; Robert J Gallop; Shireen L Rizvi; Jackie K Gollan; David L Dunner; Neil S Jacobson Journal: J Consult Clin Psychol Date: 2008-06
Authors: Somaia Mohamed; Gary R Johnson; Peijun Chen; Paul B Hicks; Lori L Davis; Jean Yoon; Theresa C Gleason; Julia E Vertrees; Kimberly Weingart; Ilanit Tal; Alexandra Scrymgeour; David D Lawrence; Beata Planeta; Michael E Thase; Grant D Huang; Sidney Zisook; Sanjai D Rao; Patricia D Pilkinton; James A Wilcox; Ali Iranmanesh; Mamta Sapra; George Jurjus; James P Michalets; Muhammed Aslam; Thomas Beresford; Keith D Anderson; Ronald Fernando; Sriram Ramaswamy; John Kasckow; Joseph Westermeyer; Gihyun Yoon; D Cyril D'Souza; Gunnar Larson; William G Anderson; Mary Klatt; Ayman Fareed; Shabnam I Thompson; Carlos J Carrera; Solomon S Williams; Timothy M Juergens; Lawrence J Albers; Clifford S Nasdahl; Gerardo Villarreal; Julia L Winston; Cristobal A Nogues; K Ryan Connolly; Andre Tapp; Kari A Jones; Gauri Khatkhate; Sheetal Marri; Trisha Suppes; Joseph LaMotte; Robin Hurley; Aimee R Mayeda; Alexander B Niculescu; Bernard A Fischer; David J Loreck; Nicholas Rosenlicht; Steven Lieske; Mitchell S Finkel; John T Little Journal: JAMA Date: 2017-07-11 Impact factor: 56.272
Authors: Zhibao Mi; Kousick Biswas; J Kaci Fairchild; Anne Davis-Karim; Ciaran S Phibbs; Steven D Forman; Michael Thase; Gerald Georgette; Tamara Beale; David Pittman; Margaret Windy McNerney; Allyson Rosen; Grant D Huang; Mark George; Art Noda; Jerome A Yesavage Journal: Trials Date: 2017-09-02 Impact factor: 2.279
Authors: Noah S Philip; Jennifer Barredo; Emily Aiken; Victoria Larson; Richard N Jones; M Tracie Shea; Benjamin D Greenberg; Mascha van 't Wout-Frank Journal: Am J Psychiatry Date: 2019-06-24 Impact factor: 18.112
Authors: Bashar W Badran; Martina Ly; William H DeVries; Chloe E Glusman; Angela Willis; Saxby Pridmore; Mark S George Journal: Brain Stimul Date: 2018-11-08 Impact factor: 8.955
Authors: Whitney T Carrico; Gerald Georgette; Michelle R Madore; F Andrew Kozel; Mark S George; Steven Lindley; Steven Lovett; Jong H Yoon; Jerome A Yesavage Journal: Fed Pract Date: 2020-06
Authors: Shan H Siddiqi; Nicholas T Trapp; Carl D Hacker; Timothy O Laumann; Sridhar Kandala; Xin Hong; Ludwig Trillo; Pashtun Shahim; Eric C Leuthardt; Alexandre R Carter; David L Brody Journal: J Neurotrauma Date: 2019-01-07 Impact factor: 5.269
Authors: Shan H Siddiqi; Stephan F Taylor; Danielle Cooke; Alvaro Pascual-Leone; Mark S George; Michael D Fox Journal: Am J Psychiatry Date: 2020-03-12 Impact factor: 18.112
Authors: Alexander McGirr; Daniel J Devoe; Amelie Raedler; Chantel T Debert; Zahinoor Ismail; Marcelo T Berlim Journal: Can J Psychiatry Date: 2020-12-23 Impact factor: 4.356
Authors: Paul E Croarkin; Ahmed Z Elmaadawi; Scott T Aaronson; G Randolph Schrodt; Richard C Holbert; Sarah Verdoliva; Karen L Heart; Mark A Demitrack; Jeffrey R Strawn Journal: Neuropsychopharmacology Date: 2020-09-12 Impact factor: 7.853